GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipum AB (OSTO:LIPUM) » Definitions » Dividend Yield %

Lipum AB (OSTO:LIPUM) Dividend Yield % : 0.00% (As of May. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lipum AB Dividend Yield %?

As of today (2024-05-20), the Trailing Annual Dividend Yield of Lipum AB is 0.00%.

The historical rank and industry rank for Lipum AB's Dividend Yield % or its related term are showing as below:

OSTO:LIPUM's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful Dividend Yield % only.

Lipum AB's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00.

As of today (2024-05-20), the Forward Dividend Yield % of Lipum AB is 0.00%.

Lipum AB's Dividends per Share for the three months ended in Dec. 2023 was kr0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Lipum AB Dividend Yield % Historical Data

The historical data trend for Lipum AB's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipum AB Dividend Yield % Chart

Lipum AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Dividend Yield %
- - - - -

Lipum AB Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lipum AB's Dividend Yield %

For the Biotechnology subindustry, Lipum AB's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipum AB's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipum AB's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Lipum AB's Dividend Yield % falls into.



Lipum AB Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Lipum AB  (OSTO:LIPUM) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Lipum AB Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Lipum AB's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipum AB (OSTO:LIPUM) Business Description

Traded in Other Exchanges
N/A
Address
Tvistevagen 48 C, Umea, SWE, 907 36
Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.

Lipum AB (OSTO:LIPUM) Headlines

No Headlines